Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E- [c(RGDfK)]2 for breast cancer imaging

Nuclear Medicine Communications

Volumn 35, Issue 4, 2014, Pages 423-432

  Ortiz Arzate, Zareth ^a,b   Santos Cuevas, Clara L ^a   Ocampo García, Blanca E ^a   Ferro Flores, Guillermina ^a   García Becerra, Rocío ^c   Estrada, Gisela ^d,f   Gómez Argumosa, Edgar ^e   Izquierdo Sánchez, Vanessa ^e  

^a INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e National Cancer Institute   (Mexico)

^f UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

MANNITOL; N,N' ETHYLENEDIAMINEDIACETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; SILICA GEL; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CT SPECT SCANNER; DOSE RESPONSE; DOSIMETRY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PURITY; DRUG RECEPTOR BINDING; FEMALE; FREEZE DRYING; GEL PERMEATION CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE; ISOTOPE LABELING; KIDNEY; LIVER; MIDDLE AGED; MOUSE; NONHUMAN; PH; RADIATION DOSE; RADIOCHEMISTRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; SUPINE POSITION; THIN LAYER CHROMATOGRAPHY; THYROID GLAND; WHOLE BODY IMAGING;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIMERIZATION; EDETIC ACID; FEMALE; FREEZE DRYING; HUMANS; HYDRAZINES; MICE; NICOTINIC ACIDS; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; RADIOCHEMISTRY; RADIOMETRY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84896706530     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000065     Document Type: Article

References (35)

1. Cervino AR, Burei M, Mansi L, Evangelista L. Molecular pathways and molecular imaging in breast cancer: an update. Nucl Med Biol 2013; 40:581-591.
2. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, et al. Patterns of avb3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET. J Nucl Med 2008; 49:255-259.
3. Taherian A, Li X, Liu Y, Haas TA. Differences in integrin expression and signaling within human breast cancer cells. BMC Cancer 2011; 11:1-15.
4. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 2004; 18:991-1006.
5. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004; 90:561-565.
6. Kummar CC. Integrin avb3 as a therapeutic target for blocking tumorinduced angiogenesis. Curr Drug Targets 2003; 4:123-131.
7. Pointer SM, Muller WJ. Integrins in mammary-stem-cell biology and breastcancer progression - a role in cancer stem cells? Integrins in stem cell and cancer initiation. J Cell Sci 2009; 122:207-214.
8. Haubner R, Kuhnast B, Mang C. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004; 15:61-69.
9. Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, et al. Integrin receptor imaging of breast cancer: a proofof- concept study to evaluate 99mTc-NC100692. J Nucl Med 2006; 47: 1434-1439.
10. Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008; 49:879-886.
11. Li Z, Cai W, Cao Q, Chen K, Wu Z, Chen X. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor avb3 integrin expression. J Nucl Med 2007; 48:1162-1171.
12. Li ZB, Chen K, Chen X. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin avb3 expression. Eur J Nucl Med Mol Imaging 2008; 35:1100-1108.
13. Luna-Gutierrez M, Ferro-Flores G, Ocampo-Garcia BE, Jimenez-Mancilla NP, Morales-Avila E, De Leon-Rodriguez LM, et al. 177Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing avb3 integrins. J Label Compd Radiopharm 2012; 50:140-148.
14. Morales-Avila E, Ferro-Flores G, Ocampo-Garcia BE, Leon-Rodriguez LM, Santos-Cuevas CL, Medina LA. Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor avb3 expression. Bioconjug Chem 2011; 22:913-922.
15. Janssen M, OyenWJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002; 17:641-646.
16. Von-Guggenberg E, Mikolajczak R, Janota B, Riccabona G, Decristoforo C. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDAHYNIC-D-Phe1,Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. J Pharm Sci 2004; 93:2497-2506.
17. Ferro-Flores G, Arteaga de Murphy C, Rodriguez-Cortes J, Pedraza-Lopez M, Ram?rez-Iglesias MT. Preparation and evaluation of 99mTc-EDDA/HYNIC- [Lys3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun 2006; 27:371-376.
18. Gonzalez-Vazquez A, Ferro-Flores G, Arteaga de Murphy C, Gutierrez- Garc?a Z. Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3- octreotide prepared from lyophilized kits. Appl Radiat Isot 2006; 64: 792-797.
19. Buijs W, Siegel JA, Boerman OC, Corstens F. Absolute organ activity estimated by five different methods of background correction. J Nucl Med 1998; 39:2167-2172.
20. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999; 40:37S-61S.
21. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46:1023-1027.
22. Bandoli G, Dolmella A, Porchia M, Refosco F, Tisato F. Structural overview of technetium compounds (1993-1999). Coord Chem Rev 2001; 214: 43-90.
23. King RC, Surfraz MB, Biagini SC, Blower PJ, Mather SJ. How do HYNICconjugated peptides bind technetium? Insights from LC-MS and stability studies. Dalton Trans 2007; 43:4998-5007.
24. King R, Surfraz MB, Finucane C, Biagini SC, Blower PJ, Mather SJ. 99mTc- HYNIC-gastrin peptides: assisted coordination of 99mTc by amino acid side chains results in improved performance both in vitro and in vivo. J Nucl Med 2009; 50:591-598.
25. Meyer T, Marshall JF, Hart IR. Expression of av integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer 1998; 77:530-536.
26. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto RGD in cancer patients. J Nucl Med 2005; 46: 1333-1341.
27. Freindorf M, Furlani TR, Kong J, Cody V, Davis FB, Davis PJ. Combined QM/ MM study of thyroid and steroid hormone analogue interactions with avb3integrin. J Biomed Biotechnol 2012; 2012:959057.
28. Davis PJ, Mousa SA, Cody V, Tang HY, Lin HY. Small molecule hormone or hormone-like ligands of integrin aVb3: implications for cancer cell behavior. Horm Cancer 2013; 4:335-342.
29. World Health Organization. Technical Report Series 611: use of ionizing radiation and radionuclides on human beings from medical research, training, and nonmedical purposes - report of a World Health Organization Expert Committee. Geneva, Switzerland: World Health Organization; 1977.
30. Bach-Gansmo T, Bogsrud TV, Skretting A. Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tclabelled NC100692. Clin Physiol Funct Imaging 2008; 28:235-239.
31. Axelsson R, Bach-Gansmo T, Castell-Conesa J, McParland BJ. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol 2010; 51:40-46.
32. Edwards D, Jones P, Haramis H, Battle M, Lear R, Barnett DJ, et al. 99mTc- NC100692, a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation. Nucl Med Biol 2008; 35:365-375.
33. Zhou Y, Shao G, Liu S. Monitoring breast tumor lung metastasis by USPECT- II/CT with an integrin a(v)b(3)-targeted radiotracer (99m)Tc-3PRGD( 2). Theranostics 2012; 2:577-588.
34. Ma Q, Ji B, Jia B, Gao S, Ji T,Wang X, et al. Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy. Eur J Nucl Med Mol Imaging 2011; 38:2145-2152.
35. Santos-Cuevas CL, Ferro-Flores FG, Arteaga de Murphy C, Pichardo- Romero PA. Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women. Nucl Med Commun 2008; 29:741-747.